Selected Publication:
SHR
Neuro
Cancer
Cardio
Lipid
Metab
Microb
Palackic, A; Popp, D; Tapking, C; Houschyar, KS; Branski, LK.
Fungal Infections in Burn Patients.
Surg Infect (Larchmt). 2021; 22(1):83-87
Doi: 10.1089/sur.2020.299
Web of Science
PubMed
FullText
FullText_MUG
- Leading authors Med Uni Graz
-
Branski Ludwik
-
Palackic Alen
- Co-authors Med Uni Graz
-
Popp Daniel
- Altmetrics:
- Dimensions Citations:
- Plum Analytics:
- Scite (citation analytics):
- Abstract:
-
Background:
Fungal burn wound infections are among the most devastating complications in patients who are severely burned. Increasing incidence of burn wound infections caused by fungi led to new challenges in diagnostic and therapeutic approaches. The wide use of broad-spectrum antibiotic agents, an increased prevalence of molds and non-Candida albicans spp., and the variety of available antifungal agents underline the importance of identifying the causative species, to initiate adequate therapy within an adequate timeframe.
Methods:
Review of the pertinent English and German literature.
Results:
Fungal burn wound infections go along with a delay of identifying the causative fungus species and can be mistaken for early bacterial burn wound infection. Recently, an increase of uncommon fungal pathogens and fungi resistance against antifungal agents has been reported. Amphotericin B and voriconazole remain the antifungal drugs used most commonly.
Conclusions:
Adequate therapy remains challenging. Early radical debridement and wound closure play an imperative part, particularly in preventing infections caused by yeasts and molds or any other agent. Prophylactic empiric pharmacologic treatment is reserved for those highly at risk for invasive burn wound infection only. Because of the emergence of drug-resistant fungi, the development of new antifungal drugs is essential for the battle against fungal burn wound infections.
- Find related publications in this database (Keywords)
-
burn
-
fungal pathogens
-
treatment